Coherus Oncology
CHRS
103 hedge funds and large institutions have $611M invested in Coherus Oncology in 2018 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 39 increasing their positions, 29 reducing their positions, and 13 closing their positions.
103% more call options, than puts
Call options by funds: $1.99M | Put options by funds: $983K
77% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 13
40% more capital invested
Capital invested by funds: $436M → $611M (+$175M)
34% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 29
10% more funds holding
Funds holding: 94 → 103 (+9)
6.53% more ownership
Funds ownership: 85.4% → 91.94% (+6.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.78M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$6.27M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$5.76M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$5.07M |
| 5 |
HCM
Highbridge Capital Management
New York
|
+$4.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$6.04M |
| 2 |
Millennium Management
New York
|
-$5.86M |
| 3 |
State Street
Boston,
Massachusetts
|
-$2.03M |
| 4 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$1.6M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.02M |
CHRS Hedge Fund Activity: Q1 2018 in Review
103 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q1 2018, worth a combined $611M — up 40% from $436M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new CHRS positions and 13 closed out — a net gain of 10 holders — while 39 added to existing stakes and 29 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $8.78M. The largest seller was State of Wisconsin Investment Board, cutting an estimated $6.04M.
- 103 institutional investors held Coherus Oncology (CHRS) as of Q1 2018, up from 94 in Q4 2017.
- Funds reported $611M of Coherus Oncology stock for Q1 2018, up 40% quarter-over-quarter.
- 23 funds opened new Coherus Oncology positions in Q1 2018 and 13 closed out, a net change of +10 holders.
- The largest Coherus Oncology buyer in Q1 2018 was Fidelity Investments, an estimated $8.78M added.
- The largest Coherus Oncology seller in Q1 2018 was State of Wisconsin Investment Board, an estimated $6.04M sold.
Based on aggregated 13F filings for Q1 2018.